



| | |
|--|--|
| Division: Pharmacy Policy | Subject: State of Florida's Agency for Health Care Administration's Prior Authorization Criteria |
| Original Development Date: Original Effective Date: Revision Date: | March 30, 2022 |

Sirturo® (bedaquiline fumarate)

LENGTH OF AUTHORIZATION: 6 months

REVIEW CRITERIA:

- Patient must be ≥ 5 years of age and ≥ 15 kg.
- Patient must have a diagnosis of pulmonary multi-drug resistant tuberculosis (MDR-TB).
- Confirmation that Sirturo will be co-administered with at least 3 other drugs proven to be effective against the patient's M. tuberculosis isolate.
- Submission of susceptibility testing.
- Prior to treatment baseline liver enzymes, ECG, and electrolytes have been obtained.

DOSING AND ADMINISTRATION:

- Refer to product labeling at <https://www.accessdata.fda.gov/scripts/cder/daf/>
- Available as 20 mg and 100mg tablets.